Tuberculosis and HIV

From a western clinical perspective, the TB–HIV relationship is a prototypical example of two epidemics amplifying one another. HIV undermines the cell‑mediated immunity that contains Mycobacterium tuberculosis, chiefly through CD4 T‑cell depletion and impaired interferon‑γ signaling, which destabilizes granulomas and promotes reactivation from latent infection. As a result, people with HIV have a several‑fold higher risk of developing active TB and are more likely to present with extrapulmonary, disseminated, or smear‑negative disease. Conversely, active TB heightens systemic inflammation (TNF‑α, IL‑6) and immune activation that can increase HIV replication; untreated coinfection is associated with faster HIV disease progression and higher mortality. These pathophysiologic insights shape diagnostics and care. Because chest radiographs may be atypical and sputum bacillary load low, molecular tests such as Xpert MTB/RIF Ultra are prioritized, and urine lipoarabinomannan (LAM) testing is recommended in advanced HIV or severe illness to expedite diagnosis. For prevention, two pillars have strong evidence: antiretroviral therapy (ART), which markedly reduces TB incidence and death among people living with HIV, and TB preventive therapy (isoniazid‑ or rifapentine‑based regimens) for those without active disease. Treatment coordination is crucial. Randomized trials support initiating ART during TB therapy to reduce mortality, with exact timing guided by CD4 count and disease site, acknowledging a higher risk of immune reconstitution inflammatory syndrome (IRIS) in some cases. Rifamycin antibiotics remain the backbone of drug‑susceptible TB therapy, yet they induce hepatic enzymes that lower concentrations of many antiretrovirals. Clinicians therefore choose compatible regimens (e.g., rifabutin in place of rifampin in selected cases, or adjusted integrase inhibitor–based ART) and monitor for hepatotoxicity and overlapping adverse effects. Drug‑resistant TB (MDR/XDR) in people with HIV requires fully oral, optimized regimens often including bedaquiline and linezolid, with attention to QT prolongation and potential interactions. Programmatically, integrated TB/HIV services, cotrimoxazole prophylaxis in advanced disease, infection‑control in clinics, and adherence support are central to reducing mortality and transmission, especially in high‑burden settings and vulnerable populations such as incarcerated people and those experiencing homelessness.

Traditional medical systems interpret TB/HIV coinfection through frameworks focused on restoring resilience while clearing pathogenic influences. In Traditional Chinese Medicine (TCM), long‑standing infections manifest as consumption with qi and yin deficiency and concomitant heat‑toxin. Therapeutic principles emphasize tonifying the body’s Zheng qi, nourishing yin and fluids, and clearing heat/toxin to support the lungs and kidneys. In Ayurveda, TB corresponds to Rajayakshma and HIV‑related wasting reflects ojas depletion; care centers on rasayana (rejuvenative) measures to rebuild strength, appetite, and resistance while pacifying aggravated doshas. In contemporary integrative practice, these perspectives are applied as adjuncts to biomedical care. During prolonged TB and HIV treatments, individualized TCM formulas or Ayurvedic preparations may be used to support appetite, weight, sleep, and mood; botanicals such as Withania somnifera (ashwagandha), Tinospora cordifolia (guduchi), and turmeric/curcumin are sometimes chosen for adaptogenic and anti‑inflammatory properties. Early research suggests curcumin and certain immunomodulatory herbs could influence host inflammatory pathways relevant to TB, but clinical trials remain small and heterogeneous, so these modalities are positioned as supportive rather than disease‑directed therapies. Acupuncture and gentle movement (qigong, yoga) may aid fatigue, breath control, and rehabilitation after pulmonary illness, aligning with mind–body strategies to reduce stress and improve quality of life. A consistent integrative tenet is safety: herbs and supplements can interact with rifamycin antibiotics and antiretrovirals through cytochrome P450 pathways, potentially altering drug levels. Collaboration between traditional practitioners and biomedical clinicians helps ensure herb‑drug interaction checks, alignment with infection‑control measures, and attention to nutrition, rest, and emotional support—domains valued across traditions. In this synthesis, traditional approaches contribute to symptom relief and resilience, while evidence‑based TB/HIV pharmacotherapy remains foundational for survival and cure.